

# Enfortumab vedotin-associated inflammatory lung disease : Clinical insights from a case series


G. Desimpel, MD<sup>1</sup>, M. Brichard, MD<sup>1</sup>, E. Gasser, MD<sup>1</sup>, N. Honoré, MD<sup>1</sup>, E. Seront, MD, PhD<sup>1</sup>

(1) Institut Roi Albert II, Department of Medical Oncology, Cliniques universitaires Saint Luc, Brussels, Belgium

## Introduction

Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) combining monomethyl auristatin E (MMAE), a potent cytotoxic agent, with a monoclonal antibody targeting nectin-4.

- EV emerged as an highly efficient therapy for metatatic urothelial carcinoma (mUC),
- either alone after failure of platinum-based chemotherapy (CT) and immune checkpoint inhibitor (ICI) (EV301 trial) ;
  - either in combination with Pembrolizumab in first line mUC (EV302 / KEYNOTE-A39 trial).



**Skin toxicity and neuropathy are commonly observed with EV. With the increasing use of EV in clinical practice, new toxicity profile may appear, including inflammatory lung disease.**

## Materials and methods




Retrospective analysis of all patients treated with EV in monotherapy for mUC between January 2023 and January 2024.

Analysis of respiratory symptoms and imaging during EV treatment.

## Results

Ten patients treated with EV following CT and ICI.

Three experienced lung infiltration on imaging during EV.

	Case n°1 : Mr. L., 71 years old	Case n°2 : Mr. L., 68 years old	Case n°3 : Mr. M., 73 years old
CT/PET-CT scans			
ILD description	<b>Bilateral pachypleuritis :</b> Bilateral pleural and subpleural thickening with PET-CT hypermetabolism	<b>Bilateral pachypleuritis :</b> Bilateral subpleural arciform consolidations and ground-glasses opacities	<b>Right pneumonitis :</b> Right upper lobe pulmonary consolidation with PET-CT hypermetabolism
Time of onset after EV start	Three months	Two months	One month
Symptoms	Dyspnea - cough	/	Dyspnea - cough
Management	EV's cessation  Corticotherapy short course (methylprednisolone 32 mg for 5 days)	EV's cessation	EV's cessation  Corticotherapy short course (methylprednisolone 32 mg for 5 days)
Resolution	Complete	Partial	Partial

## Conclusion

Pulmonary toxicity was observed in up to 30% of our patients treated with EV in monotherapy.

Imaging profile normalized after EV cessation.

Pathogenesis remains unknown but cases should be collected across registries.